

# Echelon Biosciences Inc.

## p53 DBD VHH Antibody

Z-N006

Support: echelon@echelon-inc.com



### **Description:**

Anti-human p53 VHH Antibody was raised in alpaca and purified from E. coli as a VHH single domain antibody with a COOH-terminal HA epitope tag.

### **Applications:**

Pull-down (PD), Immunoprecipitation (IP), and Enzyme-Linked Immunoassay (ELISA).

Other in vitro, in vivo, cellular, & tissue applications are possible, but have not been verified by Echelon Biosciences.

### **Properties:**

**Form** – liquid

**Storage instructions** – Store at -20 °C upon arrival. Aliquot and store at -80 °C if longer storage is necessary. Avoid repeated freeze/thaw cycles.

**Storage buffer** – 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1mM DTT, 60 % glycerol

**Concentration** – 1.0 mg/mL

**Purity** – >80%

**Immunogen** – human recombinant p53

DNA-binding domain (p53 DBD)

**Clonality** – monoclonal, Nb139

**Isotype** – VHH single domain antibody

**Tag** – C-Terminal HA

### **References:**

1. Bethuynne J, et al. (2014) A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. *Nucleic Acids Res*; 42(20):12928-12938
2. Steels, A et al. (2018) Intracellular displacement of p53 using transactivation domain (p53 TAD) specific nanobodies. *MAbs*; 10(7):1045-1059
3. Steels, A et al. (2019) Nb-induced stabilisation of p53 in HPV-infected cells. *Sci Rep*; 9(1):12680

### **Related Products:**

Products	Catalog Number
Assays and Reagents	
PTEN Activity ELISA	K-4700
PI(3,4)P2 diC8	P-3408
Nanobodies	
Pan-Akt VHH Antibody	Z-N001
FAK VHH Antibody	Z-N004
Tks5 VHH Antibody	Z-N009

### **Specificity:**

Z-N006 interacts with both human and wild type and mutant forms of p53 DBD. No cross reactivity with p63/p73 was observed. Reactivity with other species has not been tested.

### **Background:**

p53 is a well-studied tetrameric transcription factor and tumor suppressor. Once described as 'guardian of the genome', it controls numerous aspects of cellular behavior. Mutations in p53 are observed in over 50% of cancers with several hot spot mutations occurring in the DNA binding domain.

Technical Data Sheet Rev. 1a, 08-20-21 - For research use only. Not intended or approved for diagnostic or therapeutic use.



Echelon Biosciences Inc.

Ph: 866-588-0455

Fax: 801-588-0497

Echelon-inc.com